Bafilomycin B1, a macrolide antibiotic isolated from Streptomyces sp, acts as an inhibitor of K+-dependent ATPase of E. coli. It also inhibits Gram-positive bacteria and fungi.
Polymyxin B1, a potent antimicrobial lipopeptide derived from Bacillus polymyxa, has potential for treating multidrug-resistant Gram-negative bacterial infections.
Enniatin B1 crosss the blood-brain barrier. Enniatin B1 decreases the activation of ERK (p44 p42). Enniatin B1 inhibits moderately TNF-α-induced NF-κB activation.Enniatin B1 is a Fusarium mycotoxin. Enniatin B1 inhibits acyl-CoA: cholesterol acyltransferase (ACAT) activity with an IC50 of 73 μM in an enzyme assay using rat liver microsomes.
Thielocin B1 is a protein-protein interaction inhibitor of PAC3 homodimer. Thielocin B1 was isolated as a novel phospholipase A2 inhibitor from the fermentation broth of Thielavia terricola RF-143.
Thromboxane B2 (TXB2) is released in substantial quantities from aggregating platelets and metabolized during circulation to 11-dehydro TXB2 and 2,3-dinor TXB2. In rats and rabbits, 2,3-dinor TXB1 has been identified as another urinary metabolite of TXB2. However in human urine, only trace amounts of 2,3-dinor TXB1 have been identified. In rats, 2,3-dinor TXB1 is excreted at a much higher rate than 2,3-dinor TXB2 (19.2 ± 4.9 ng/24 hr and 1.6 ± 0.3 ng/24 hr, respectively). Therefore, urinary 2,3-dinor TXB1 is a suitable marker of thromboxane biosynthesis in rats.